1 / 30

published online November 12, 2013; Circulation. DOI: 10.1161/01.cir.0000437738.63853.7a

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. published online November 12, 2013;

salim
Download Presentation

published online November 12, 2013; Circulation. DOI: 10.1161/01.cir.0000437738.63853.7a

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines published online November 12, 2013; Circulation. DOI: 10.1161/01.cir.0000437738.63853.7a

  2. Classification of Recommendation and Level of Evidence

  3. NHLBI Grading the Strength of Recommendations

  4. NHLBI Grading the Strength of Recommendations (Conti.... from prev. page)

  5. Quality Rating the Strength of Evidence

  6. 4 groups of patients to be treated with statin (in which the potential for an ASCVD risk reduction benefit clearly exceeds the potential for adverse effects) Adults who are: 1. Individuals with clinical ASCVD 2. Individuals with primary elevations of LDL–C ≥190 mg/dL 3. Individuals 40 to 75 years of age with diabetes with LDL-C 70-189 mg/dL 4. Individuals without clinical ASCVD or diabetes who are 40 to 75 years of age with LDL-C 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher ASCVD: AtheroSclerotic CardioVascular Disease, It includes coronary heart disease (CHD), stroke, and peripheral arterial disease, all of presumed atherosclerotic origin

  7. High- Moderate- and Low-Intensity Statin Therapy

  8. Major recommendations for statin therapy for ASCVD prevention

  9. Major recommendations for statin therapy for ASCVD prevention (Conti.... from prev. page)

  10. Initiating statin therapy in individuals with clinical ASCVD

  11. Initiating statin therapy in individuals without clinical ASCVD

  12. Initiating statin therapy in individuals without clinical ASCVD (Conti.... from prev. page)

  13. Statin Therapy: Monitoring therapeutic response and adherence

  14. Summary of Recommendations for Monitoring, Optimizing, and Insufficient Response to Statin Therapy

  15. Summary of Recommendations for Monitoring, Optimizing, and Insufficient Response to Statin Therapy

  16. Summary of Recommendations for Monitoring, Optimizing, and Insufficient Response to Statin Therapy(Conti.... from prev. page)

  17. Statin Safety Recommendations

  18. Statin Safety Recommendations (Conti.... from prev. page)

  19. Statin Safety Recommendations (Conti.... from prev. page)

  20. Statin Safety Recommendations (Conti.... from prev. page)

  21. Statin Safety Recommendations (Conti.... from prev. page)

  22. Details of recommendations for statins No specific targets for LDL/non-HDL anymore!

  23. Details of recommendations for statins(Conti.... from prev. page)

  24. Details of recommendations for statins(Conti.... from prev. page)

  25. Details of recommendations for statins(Conti.... from prev. page)

  26. Details of recommendations for statins(Conti.... from prev. page)

  27. Details of recommendations for statins(Conti.... from prev. page)

  28. Safety Recommendations for Nonstatin drugs(Conti.... from prev. page)

  29. Safety Recommendations for Nonstatin drugs(Conti.... from prev. page)

  30. Safety Recommendations for Nonstatin drugs(Conti.... from prev. page)

More Related